I see. Biden is saving lives with Trump vaccines. Yeh. Everyone knows that. Just sayin his covid death numbers are exceeded Trump's so it would be nice if he and you would start delivering something more than Trump's vaccines.
I've seen different models about the number of lives saved by Covid vaccinations but I'm trying to find an article that talks about the financial savings involving saving that many lives. Regardless, I'm starting to see more and more articles in the past two weeks along with the number of lives being saved in particular groups. Business savings too because they do not need to retrain a new employee that's replacing someone that has died from Covid or hospitalized from Covid. Then there's the family household savings and prevention of a financial disaster when the head of the household dies from Covid or is hospitalized for an extended period of time. I have a friend and when his wife died from Covid, she's young and didn't have life insurance. He sold their house about 7 months later. Next, him and his kids moved back home with his parents just for some stability in the children's life. It's that type of cost that's not very easy to measure financially. wrbtrader
I read that Iceland has stopped the Moderna jab due to heart inflammation concerns. They have ample supply of Pfizer. Thought it had the same side effects???
The Moderna vaccine has a higher rate of myocarditis as a side effect compared to Pfizer — even though it is still very rare. It is commonly found in males under 30 as a side effect. While actually catching Covid has a high rate of long term heart impacts in the young — in some studies hundreds of times more than any vaccine side effects. At this point it is my understanding that Norway, Sweden, Finland, Denmark and Iceland have recently paused using Moderna vaccine in those under age 30. The Modena vaccine has 3 times the dose of the Pfizer vaccine. While both use similar mRNA technology — the dosage differential is significant for side effects. Yet the Moderna vaccine wanes less over time and has greater protection against hospitalization.
You being from the United States and older...you should know that Moderna is not approved for people under 18 years of age. My teenagers are vaccinated with Pfizer but several months later...Moderna was approved here in Canada for 12 - 18 years old. In another thread about Myocarditis...I discussed its connection to other vaccines such as the FLU and my own heart inflammation from Myocarditis when I was a teenager (still growing) along with other problems like Heart Murmur...both went away in a very short time after a change in diet and change in my exercise routine...the latter my Doctor had mentioned became an issue because of my intense rowing / cardio work as a youth in which I was still growing fast. Both had appeared within a month after I received the FLU vaccine. Both later cleared up on their own...as stated with a change in diet and change in my exercise routine. With that said, all vaccines have mild side effects but Myocarditis is not a big concern because it fixes itself quickly when most don't know they have it. The real problem is when you have an underlying medical condition that you did not know about (1/3 of the population that thinks it is healthy...do in fact have an underlying medical condition)... Myocarditis showing up from any type of vaccination while a person already has an existing underlying medical condition can quickly become problematic although very rare. Regardless, as stated multiple times...some people are not suitable for vaccination because of something they're doing or occurring in their personal life. The above is the reason why I had a complete medical exam that included blood chemistry work to determine which Covid vaccine was suitable for me and which were not. It was determine that AstraZeneca and J&J were dangerous for me (allergic to some of the ingredients) while Moderna was suitable for me. I then had a complete medical exam and blood chemistry work again about 30 days after my Covid vaccination due to a recent allergic reaction to a medication when I was hospitalized in 2016 and due to my prior medical history with Myocarditis and a Heart Murmur when I was a youth. The same medical exams were given to my teenagers (before/after Pfizer vaccination), considering they are heavily involved in sports too and growing fast. Myocarditis is rare but even more rare to be hospitalized or die from it. Yet, Moderna is still not approved for youth in the United States while recently approved for use here in Canada for youths. I hope Canada revisits their recent approval of Moderna for those < 18 years of age. rbtrader
Russia furiously denies stealing AstraZeneca ‘blueprint’ to make Sputnik V COVID-19 vaccine https://fortune.com/2021/10/12/russ...blueprint-to-make-sputnik-v-covid-19-vaccine/ Russia and the team behind its Sputnik V COVID-19 vaccine have strenuously denied U.K. tabloid reports that claimed Russian spies stole the "blueprint" for the Oxford/AstraZeneca jab and used it to "help create" Sputnik V. The article in question, published Monday in The Sun, said British security services had told ministers that the data was "stolen by a foreign agent in person," and that the Sputnik jab was "copied" from AstraZeneca's. The article tied the incident to a warning issued over a year ago by British, Canadian and American intelligence, saying the Russian state-linked hacking group Cozy Bear had almost certainly targeted Western vaccine developers. The Sun piece elicited a short, sharp response from the Kremlin, whose spokesman Dmitry Peskov observed that the British tabloid was "a very well-known and a very unscientific newspaper." The Russian Direct Investment Fund (RDIF), which promotes and sells Sputnik V, went considerably further in a statement issued late Monday. "U.K. media reports that Russia’s Sputnik V was allegedly based on research from the Oxford/AstraZeneca vaccine is another fake news and blatant lie based on anonymous sources," it thundered. The Sun's claims "also make absolutely no sense scientifically as Sputnik V and AstraZeneca use different platforms," RDIF noted. The two vaccines share similar technology, with both using modified versions of pre-existing adenoviruses—a kind of virus that causes colds and bronchitis—to deliver the necessary genetic code to the recipient, triggering the immune response that provides inoculation against SARS-CoV-2. That said, there are significant differences between AstraZeneca's vaccine and Sputnik V. AstraZeneca's vaccine uses a modified version of a chimpanzee adenovirus. Conversely, Sputnik V uses human adenoviruses that the jab's developer, the Gamaleya Center, has previously used for an Ebola vaccine—each of Sputnik V's two doses is based on a different adenovirus, whereas all the other COVID-19 vaccines, AstraZeneca included, use the same substance repeatedly. "We find such attacks highly unethical as they undermine the global vaccination effort," sniffed RDIF, an outfit that has regularly used social media to attack rivals including AstraZeneca. "Rather than spreading fake stories, the U.K. media and government services should better protect the reputation of AstraZeneca, a safe and efficient vaccine that is constantly attacked by competitors in the media with facts taken out of context." AstraZeneca itself declined to comment on the Sun report. Meanwhile, a U.K. government spokesperson said they had seen the article but would not "comment on matters on the intelligence front." "We take any such accusations of intellectual property theft and cyberattacks extremely seriously, and we’ve called out attempts in the past," the spokesperson said. Sputnik V has been approved for use in 70 countries now, with its most recent green light coming from Indonesian drug regulators in late August. However, it is still yet to be approved by the World Health Organization, which is a precondition to its inclusion in the global COVAX vaccine-procurement scheme for low- and middle-income countries. Notably, the European Medicines Agency (EMA) is also yet to clear Sputnik V for emergency use within the European Union; without this approval, people who have been vaccinated with Sputnik V find it more difficult to travel in the EU. The EU's ambassador to Russia, Markus Ederer, said Friday that Russia was holding up the process by repeatedly postponing an EMA inspection in the country.
Vaccines cut the risk of severe COVID-19 by at least 90% in a huge real-world study of 23 million people https://www.businessinsider.com/cov...ness-severe-disease-french-study-data-2021-10
This article delves deeper into the financial impact of Covid across society and households. NPR poll: The delta surge pushed Americans further behind in all walks of life https://www.npr.org/sections/health...americans-further-behind-in-all-walks-of-life
As expected it is unlikely that the FDA staff will recommend a booster for Moderna at this point in time. The Moderna dose was three times greater than Pfizers and there is little waning of initial two shot efficacy being seen. U.S. FDA staff says Moderna did not meet all criteria for COVID-19 boosters https://www.reuters.com/business/he...-clearance-older-adults-high-risk-2021-10-12/ Scientists at the U.S. Food and Drug Administration said on Tuesday that Moderna Inc (MRNA.O) had not met all of the agency's criteria to support use of booster doses of its COVID-19 vaccine, possibly because the efficacy of the shot's first two doses has remained strong. FDA staff said in documents that data for Moderna's vaccine showed that a booster does increase protective antibodies, but the difference in antibody levels before and after the shot was not wide enough, particularly in those whose levels had remained high. The documents were released ahead of a meeting later this week of the FDA's outside expert advisers to discuss booster doses of the vaccine. The FDA typically follows the advice of its experts, but is not bound to do so. A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) will meet next week to discuss specific recommendations on who can receive the boosters, if the FDA authorizes them. "There was boosting, sure. Was it enough boosting? Who knows? There’s no standard amount of boosting that is known to be needed, and nor is it clear how much boosting happened in the study,” John Moore, a professor of microbiology and immunology at Weill Cornell Medical College in New York, said in an email. Moderna is seeking authorization for a 50-microgram booster dose, half the strength of the original vaccine given in two shots about four weeks apart. The company has asked regulators to clear a third round of shots for adults aged 65 and over, as well as for high-risk individuals, similar to the authorization gained by rivals Pfizer Inc(PFE.N)and German partner BioNTech for their mRNA vaccine. President Joe Biden's administration announced plans earlier this year to roll out booster doses for most adults, but some FDA scientists later said in an article in journal The Lancet that there was not enough evidence to support boosters for all. Data on the need for boosters has largely come from Israel, which rolled out the additional shots of the Pfizer/BioNTech vaccine to large swaths of its population, and has provided details on the effectiveness of that effort to U.S. advisers. No similar real-world study populations exist for the Moderna or Johnson & Johnson(JNJ.N)vaccines. The evidence for Moderna's booster appears to have "a lot of holes," said Dr. Eric Topol, a professor of molecular medicine and director of the Scripps Research Translational Institute in La Jolla, California, noting that the data provided was limited and offers no insight into how the boosters actually perform in people. "That is fairly short of what Pfizer had from Israel, where they had the full restoration of the vaccine effectiveness from the booster," Topol said. The FDA's advisers will also consider booster doses for J&J's single-dose vaccine on Friday. The FDA has not yet released its briefing documents on those shots. J&J has asked the FDA to authorize a booster at least two months after the initial shot. It said data suggests high-risk adults should receive boosters earlier, but that lower-risk individuals could benefit from waiting at least six months for their second shot. Reporting by Michael Erman in New Jersey, Julie Steenhuyen in Chicago and Manas Mishra in Bengaluru; Editing by Arun Koyyur and Bill Berkrot